How to buy Madrigal Pharmaceuticals stock (MDGL)

Madrigal Pharmaceuticals is a biotechnology business based in the US. Madrigal Pharmaceuticals shares (MDGL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $313.11 – an increase of 1.51% over the previous week. Madrigal Pharmaceuticals employs 376 staff and has a trailing 12-month revenue of around $76.8 million.

Our top picks for where to buy Madrigal Pharmaceuticals stock

Buy Madrigal Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Madrigal Pharmaceuticals stock price (NASDAQ: MDGL)

Use our graph to track the performance of MDGL stocks over time.

Madrigal Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$313.11
52-week range	$168.25 - $368.29
50-day moving average more info button	$292.75
200-day moving average more info button	$257.53
Wall St. target price	$373.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-25.02

Is it a good time to buy Madrigal Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Madrigal Pharmaceuticals price performance over time

Historical closes compared with the close of $314.04 from 2024-12-26

1 week (2024-12-20)	1.82%
1 month (2024-11-27)	-5.25%
3 months (2024-09-27)	47.83%
6 months (2024-06-28)	12.09%

1 year (2023-12-28)	34.21%
2 years (2022-12-28)	15.95%
3 years (2021-12-28)	281.30%
5 years (2019-12-27)	236.84%

Madrigal Pharmaceuticals financials

Revenue TTM	$76.8 million
Gross profit TTM	$0
Return on assets TTM	-52.25%
Return on equity TTM	-129.76%
Profit margin	0%
Book value	$35.64
Market Capitalization more info button	$6.8 billion

TTM: trailing 12 months

Madrigal Pharmaceuticals share dividends

We're not expecting Madrigal Pharmaceuticals to pay a dividend over the next 12 months.

Have Madrigal Pharmaceuticals's shares ever split?

Madrigal Pharmaceuticals's shares were split on a 1:35 basis on 24 July 2016 . So if you had owned 35 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Madrigal Pharmaceuticals shares – just the quantity. However, indirectly, the new 3400% higher share price could have impacted the market appetite for Madrigal Pharmaceuticals shares which in turn could have impacted Madrigal Pharmaceuticals's share price.

Madrigal Pharmaceuticals share price volatility

Over the last 12 months, Madrigal Pharmaceuticals's shares have ranged in value from as little as $168.2462 up to $368.29. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Madrigal Pharmaceuticals's is -0.469. This would suggest that Madrigal Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Madrigal Pharmaceuticals has bucked the trend.

Madrigal Pharmaceuticals overview

Madrigal Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. .

Frequently asked questions

What percentage of Madrigal Pharmaceuticals is owned by insiders or institutions?
Currently 8.563% of Madrigal Pharmaceuticals shares are held by insiders and 105.556% by institutions. How many people work for Madrigal Pharmaceuticals?
Latest data suggests 376 work at Madrigal Pharmaceuticals. When does the fiscal year end for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals's fiscal year ends in December. Where is Madrigal Pharmaceuticals based?
Madrigal Pharmaceuticals's address is: Four Tower Bridge, West Conshohocken, PA, United States, 19428 What is Madrigal Pharmaceuticals's ISIN number?
Madrigal Pharmaceuticals's international securities identification number is: US5588681057 What is Madrigal Pharmaceuticals's CUSIP number?
Madrigal Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 87162T206